301089 拓新药业
已收盘 07-29 15:00:00
资讯
新帖
简况
拓新药业:公司2024年6月28日股东人数请您届时查看公司2024年半年度报告
证券之星 · 07-08
拓新药业:公司2024年6月28日股东人数请您届时查看公司2024年半年度报告
拓新药业:截至2024年6月20日,公司股东户数22,784户
证券之星 · 06-26
拓新药业:截至2024年6月20日,公司股东户数22,784户
拓新药业:截至2024年5月31日,公司股东户数22,702户
证券之星 · 06-03
拓新药业:截至2024年5月31日,公司股东户数22,702户
拓新药业(301089.SZ)拟10股派2.5元 于5月23日除权除息
智通财经 · 05-15
拓新药业(301089.SZ)拟10股派2.5元 于5月23日除权除息
拓新药业(301089)4月30日股东户数2.17万户,较上期减少12.72%
证券之星 · 05-09
拓新药业(301089)4月30日股东户数2.17万户,较上期减少12.72%
拓新药业、瑞丰高材等澄清合成生物项目影响:业务占比低 商业化存不确定性
证券时报·e公司 · 05-08
拓新药业、瑞丰高材等澄清合成生物项目影响:业务占比低 商业化存不确定性
拓新药业最新公告:合成生物学相关产品实现的收入占营业收入的比例不足5%
证券之星 · 05-08
拓新药业最新公告:合成生物学相关产品实现的收入占营业收入的比例不足5%
合成生物现分化!大牛股晋级5连板,政策预期还没打满?
格隆汇 · 05-07
合成生物现分化!大牛股晋级5连板,政策预期还没打满?
异动快报:拓新药业(301089)5月7日10点52分触及涨停板
证券之星 · 05-07
异动快报:拓新药业(301089)5月7日10点52分触及涨停板
拓新药业:公司专注于核苷(核苷酸)类医药中间体及原料药,主要涵盖抗病毒、抗肿瘤和神经系统用药领域
证券之星 · 04-25
拓新药业:公司专注于核苷(核苷酸)类医药中间体及原料药,主要涵盖抗病毒、抗肿瘤和神经系统用药领域
拓新药业(301089)2024年一季报简析:净利润减99.32%,三费占比上升明显
证券之星 · 04-24
拓新药业(301089)2024年一季报简析:净利润减99.32%,三费占比上升明显
拓新药业(301089.SZ)发布一季度业绩,净利润206.84万元,下降99.32%
智通财经 · 04-22
拓新药业(301089.SZ)发布一季度业绩,净利润206.84万元,下降99.32%
拓新药业(301089.SZ)发布2023年度业绩,净利润2.43亿元,下降15.17%
智通财经 · 04-22
拓新药业(301089.SZ)发布2023年度业绩,净利润2.43亿元,下降15.17%
拓新药业(301089.SZ)监事董春红减持期满 共减持1000股
智通财经网 · 03-07
拓新药业(301089.SZ)监事董春红减持期满 共减持1000股
公司概况
公司名称:
拓新药业集团股份有限公司
所属行业:
医药制造业
上市日期:
2021-10-27
主营业务:
拓新药业集团股份有限公司是集化学合成、生物发酵核苷(酸)类原料药及医药中间体的研发、生产及销售为一体的高新技术企业。主要产品有嘧啶系列、嘌呤系列、核苷酸系列、核苷系列等多个系列核苷(酸)类产品,包括胞磷胆碱钠、利巴韦林、肌苷、阿昔洛韦、胞嘧啶、5-氟胞嘧啶、胞苷等原料药及医药中间体,主要涵盖抗病毒、抗肿瘤和神经系统用药领域。被认定为“国家高技术产业示范工程”,获得国家科学技术进步二等奖等重大科技奖项。公司及子公司已获得境内授权专利 9 项。
发行价格:
19.11
{"stockData":{"symbol":"301089","market":"SZ","secType":"STK","nameCN":"拓新药业","latestPrice":30.17,"timestamp":1722236598000,"preClose":30.53,"halted":0,"volume":1697823,"delay":0,"floatShares":78882400,"shares":127000000,"eps":-0.4676,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.36,"latestTime":"07-29 15:00:00","open":30.52,"high":30.53,"low":29.99,"amount":51292000,"amplitude":0.0177,"askPrice":30.19,"askSize":79,"bidPrice":30.17,"bidSize":70,"shortable":0,"etf":0,"ttmEps":-0.4676,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1722303000000},"adr":0,"adjPreClose":30.53,"symbolType":"stock","openAndCloseTimeList":[[1722216600000,1722223800000],[1722229200000,1722236400000]],"highLimit":33.58,"lowLimit":27.48,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":126544500,"pbRate":2.41,"roa":"--","roe":"0.13%","epsLYR":1.93,"committee":-0.449024,"marketValue":3818000000,"floatMarketCap":2380000000,"peRate":-64.52096,"changeRate":-0.0118,"turnoverRate":0.0215,"status":1},"requestUrl":"/m/hq/s/301089/wiki","defaultTab":"wiki","newsList":[{"id":"2449775367","title":"拓新药业:公司2024年6月28日股东人数请您届时查看公司2024年半年度报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2449775367","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449775367?lang=zh_cn&edition=full","pubTime":"2024-07-08 19:01","pubTimestamp":1720436494,"startTime":"0","endTime":"0","summary":"证券之星消息,拓新药业07月08日在投资者关系平台上答复投资者关心的问题。谢谢拓新药业董秘:公司2024年6月28日股东人数请您届时查看公司2024年半年度报告,感谢您的关注!","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070800025826.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301089"],"gpt_icon":0},{"id":"2446669063","title":"拓新药业:截至2024年6月20日,公司股东户数22,784户","url":"https://stock-news.laohu8.com/highlight/detail?id=2446669063","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446669063?lang=zh_cn&edition=full","pubTime":"2024-06-26 19:01","pubTimestamp":1719399684,"startTime":"0","endTime":"0","summary":"证券之星消息,拓新药业(301089)06月26日在投资者关系平台上答复投资者关心的问题。投资者:第二季度业绩如何?有没有被st的可能?拓新药业董秘:具体业绩情况请您关注公司定期报告。感谢您的关注!投资者:请问截止到2024年6月20日公司收盘股东人数是多少?谢谢拓新药业董秘:截至2024年6月20日,公司股东户数22,784户。感谢您的关注!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062600037502.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301089","BK0239"],"gpt_icon":0},{"id":"2440248466","title":"拓新药业:截至2024年5月31日,公司股东户数22,702户","url":"https://stock-news.laohu8.com/highlight/detail?id=2440248466","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440248466?lang=zh_cn&edition=full","pubTime":"2024-06-03 19:01","pubTimestamp":1717412499,"startTime":"0","endTime":"0","summary":"证券之星消息,拓新药业(301089)06月03日在投资者关系平台上答复投资者关心的问题。投资者:请问最新的股东户数是多少?拓新药业董秘:截至2024年5月31日,公司股东户数22,702户。感谢您的关注!投资者:请问截止至2024年5月31日公司股东人数总数是多少?谢谢拓新药业董秘:截至2024年5月31日,公司股东户数22,702户。感谢您的关注!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060300023960.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301089","BK0239"],"gpt_icon":0},{"id":"2435636699","title":"拓新药业(301089.SZ)拟10股派2.5元 于5月23日除权除息","url":"https://stock-news.laohu8.com/highlight/detail?id=2435636699","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435636699?lang=zh_cn&edition=full","pubTime":"2024-05-15 19:20","pubTimestamp":1715772041,"startTime":"0","endTime":"0","summary":"智通财经APP讯,拓新药业(301089.SZ)公告,公司2023年年度权益分派拟:每10股派2.5元(含税);除权除息日为:2024年5月23日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1121633.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301089","BK0239"],"gpt_icon":0},{"id":"2434066804","title":"拓新药业(301089)4月30日股东户数2.17万户,较上期减少12.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2434066804","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434066804?lang=zh_cn&edition=full","pubTime":"2024-05-09 17:03","pubTimestamp":1715245399,"startTime":"0","endTime":"0","summary":"证券之星消息,近日拓新药业披露,截至2024年4月30日公司股东户数为2.17万户,较3月31日减少3157.0户,减幅为12.72%。在化学制药行业个股中,拓新药业股东户数低于行业平均水平,截至4月30日,化学制药行业平均股东户数为3.3万户。从股价来看,2024年3月31日至2024年4月30日,拓新药业区间跌幅为17.39%,在此期间股东户数减少3157.0户,减幅为12.72%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050900030706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301089"],"gpt_icon":0},{"id":"2433268767","title":"拓新药业、瑞丰高材等澄清合成生物项目影响:业务占比低 商业化存不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2433268767","media":"证券时报·e公司","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433268767?lang=zh_cn&edition=full","pubTime":"2024-05-08 21:09","pubTimestamp":1715173740,"startTime":"0","endTime":"0","summary":"5月8日晚间,拓新药业、瑞丰高材、蔚蓝生物等多家公司均发布股票交易异常波动公告,对合成生物等相关概念影响进行说明并作出风险提示。与拓新药业类似,本周大涨逾30%的瑞丰高材当晚亦发布股票异常波动公告,对外界关注的合成生物材料、黑磷材料等新业务进行澄清说明。除了上述3家公司之外,近日包括圣达生物等在内多家公司均提示过合成生物学相关项目尚不具备产业化条件等风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405082109577a58c27f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405082109577a58c27f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["300243","BK0177","BK0086","BK0239","BK0028","603739","301089","BK0226","BK0229"],"gpt_icon":0},{"id":"2433874241","title":"拓新药业最新公告:合成生物学相关产品实现的收入占营业收入的比例不足5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2433874241","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433874241?lang=zh_cn&edition=full","pubTime":"2024-05-08 19:30","pubTimestamp":1715167822,"startTime":"0","endTime":"0","summary":"拓新药发布股票交易异常波动的公告,目前公司积极开展合成生物学相关技术在核苷、核苷酸类产品领域的应用研究,相关技术应用于部分产品的生产,2023年度,该类产品实现的收入占营业收入的比例不足5%,占比较低,未来发展情况具有较大的不确定性。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050800035166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301089"],"gpt_icon":0},{"id":"2433197672","title":"合成生物现分化!大牛股晋级5连板,政策预期还没打满?","url":"https://stock-news.laohu8.com/highlight/detail?id=2433197672","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433197672?lang=zh_cn&edition=full","pubTime":"2024-05-07 13:29","pubTimestamp":1715059745,"startTime":"0","endTime":"0","summary":"后续还有重磅政策","market":"us","thumbnail":"https://img3.gelonghui.com/e40e3-574c6d84-58d7-499d-b7d7-17e78bc8614c.jpg?guru_height=853&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/e40e3-574c6d84-58d7-499d-b7d7-17e78bc8614c.jpg?guru_height=853&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/727112","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0168","603079","BK0188","603739","BK0226","301089","301258","BK0046","BK0239","600789"],"gpt_icon":0},{"id":"2433296364","title":"异动快报:拓新药业(301089)5月7日10点52分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2433296364","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433296364?lang=zh_cn&edition=full","pubTime":"2024-05-07 10:55","pubTimestamp":1715050523,"startTime":"0","endTime":"0","summary":"证券之星5月7日盘中消息,10点52分拓新药业触及涨停板。目前价格41.59,上涨19.99%。其所属行业化学制药目前上涨。领涨股为富士莱。该股为化学原料药,新冠病毒防治,医药概念热股,当日化学原料药概念上涨0.65%,新冠病毒防治概念上涨0.46%,医药概念上涨0.12%。5月6日的资金流向数据方面,主力资金净流出45.01万元,占总成交额0.38%,游资资金净流出115.84万元,占总成交额0.97%,散户资金净流入160.86万元,占总成交额1.35%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050700017382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301089"],"gpt_icon":0},{"id":"2430140653","title":"拓新药业:公司专注于核苷(核苷酸)类医药中间体及原料药,主要涵盖抗病毒、抗肿瘤和神经系统用药领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2430140653","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430140653?lang=zh_cn&edition=full","pubTime":"2024-04-25 19:02","pubTimestamp":1714042932,"startTime":"0","endTime":"0","summary":"拓新药业董秘:公司研发成果请您关注公司披露的公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500039625.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","301089","159938","BK0239","09939","BK1515"],"gpt_icon":0},{"id":"2429257711","title":"拓新药业(301089)2024年一季报简析:净利润减99.32%,三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2429257711","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429257711?lang=zh_cn&edition=full","pubTime":"2024-04-24 06:22","pubTimestamp":1713910974,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期拓新药业发布2024年一季报。根据财报显示,本报告期中拓新药业净利润减99.32%,三费占比上升明显。截至本报告期末,公司营业总收入1.08亿元,同比下降80.34%,归母净利润206.84万元,同比下降99.32%。公司最新一期年度报表的现金流为正,经营性现金流相对利润差距较大,建议重点核实下原因。从公司近一年的财务报表来看,最新年度财报中营收和利润同比双双下降,分别下降80%与100%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400012279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301089"],"gpt_icon":0},{"id":"2429940782","title":"拓新药业(301089.SZ)发布一季度业绩,净利润206.84万元,下降99.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429940782","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429940782?lang=zh_cn&edition=full","pubTime":"2024-04-22 20:12","pubTimestamp":1713787974,"startTime":"0","endTime":"0","summary":"智通财经APP讯,拓新药业(301089.SZ)发布2024年一季度报告,报告期内实现营业收入1.08亿元,同比下降80.34%。归属于上市公司股东的净利润206.84万元,同比下降99.32%。归属于上市公司股东的扣除非经常性损益净亏损64.14万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1106877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301089"],"gpt_icon":0},{"id":"2429940786","title":"拓新药业(301089.SZ)发布2023年度业绩,净利润2.43亿元,下降15.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429940786","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429940786?lang=zh_cn&edition=full","pubTime":"2024-04-22 20:11","pubTimestamp":1713787864,"startTime":"0","endTime":"0","summary":"智通财经APP讯,拓新药业(301089.SZ)发布2023年年度报告,报告期内,公司实现营业收入8.36亿元,同比增长6.47%。实现归属于上市公司股东的净利润2.43亿元,同比下降15.17%。实现归属于上市公司股东的扣除非经常性损益的净利润2.32亿元,同比下降16.07%。基本每股收益为1.93元。拟向全体股东每10股派发现金红利2.5元(含税)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1106872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301089"],"gpt_icon":0},{"id":"2417739827","title":"拓新药业(301089.SZ)监事董春红减持期满 共减持1000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2417739827","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2417739827?lang=zh_cn&edition=full","pubTime":"2024-03-07 16:32","pubTimestamp":1709800320,"startTime":"0","endTime":"0","summary":"拓新药业(301089.SZ)公告,公司收到董事渠桂荣、监事董春红分别出具的《关于股份减持计划实施时间届满暨减持结果的告知函》,截至告知函出具日,董事渠桂荣、监事董春红分别通过集中竞价交易方式减持0股、1000股,减持计划实施时间已届满。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-07/doc-inamnsyn9027523.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-07/doc-inamnsyn9027523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","301089"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-10-27","address":"河南省新乡市红旗区高新区科隆大道515号","stockEarnings":[{"period":"1week","weight":-0.0343},{"period":"1month","weight":0.0169},{"period":"3month","weight":-0.0936},{"period":"6month","weight":-0.2139},{"period":"1year","weight":-0.5127},{"period":"ytd","weight":-0.4378}],"companyName":"拓新药业集团股份有限公司","boardCode":"AI0027","perCapita":"3462股","boardName":"医药制造业","registeredCapital":"12654万元","compareEarnings":[{"period":"1week","weight":-0.0244},{"period":"1month","weight":-0.0255},{"period":"3month","weight":-0.0686},{"period":"6month","weight":0.037},{"period":"1year","weight":-0.1172},{"period":"ytd","weight":-0.0279}],"survey":" 拓新药业集团股份有限公司是集化学合成、生物发酵核苷(酸)类原料药及医药中间体的研发、生产及销售为一体的高新技术企业。主要产品有嘧啶系列、嘌呤系列、核苷酸系列、核苷系列等多个系列核苷(酸)类产品,包括胞磷胆碱钠、利巴韦林、肌苷、阿昔洛韦、胞嘧啶、5-氟胞嘧啶、胞苷等原料药及医药中间体,主要涵盖抗病毒、抗肿瘤和神经系统用药领域。被认定为“国家高技术产业示范工程”,获得国家科学技术进步二等奖等重大科技奖项。公司及子公司已获得境内授权专利 9 项。","serverTime":1722299641541,"listedPrice":19.11,"stockholders":"22784人(较上一季度增加0.36%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"拓新药业(301089)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供拓新药业(301089)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"拓新药业,301089,拓新药业股票,拓新药业股票老虎,拓新药业股票老虎国际,拓新药业行情,拓新药业股票行情,拓新药业股价,拓新药业股市,拓新药业股票价格,拓新药业股票交易,拓新药业股票购买,拓新药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"拓新药业(301089)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供拓新药业(301089)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}